Brief: Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study

Talphera

03/10/2023 14:11

Oct 3 (Reuters) - AcelRx Pharmaceuticals Inc  ACRX.O :
    * ACELRX RECEIVES IDE APPROVAL FOR NIYAD AND ADVANCES TO A
SINGLE
REGISTRATION STUDY
    * ACELRX PHARMACEUTICALS - INVESTIGATIONAL DEVICE EXEMPTION
APPROVAL BY FDA ALLOWS ACELRX TO BEGIN PIVOTAL STUDY OF NIYAD
    * ACELRX PHARMACEUTICALS - SINGLE REGISTRATION STUDY WITH
PRE-AGREED UPON ENDPOINTS PLANNED TO INITIATE IN Q4 2023 WITH
TOPLINE DATA EXPECTED MID-2024
    * ACELRX PHARMACEUTICALS INC - CLINICAL SITE READINESS IS
CURRENTLY UNDERWAY

Source text for Eikon:  ID:nPnHsNL4a 
Further company coverage:  ACRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))